SCHEMBL24098399

SCHEMBL24098399

Cc1cc(-c2cnccc2C)ccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.56
NFATC1 O95644 1/20 0.56
ABL1 P00519 5/20 0.53
CYP11B1 P15538 5/20 0.51
CYP11B2 P19099 5/20 0.51
CYP1A2 P05177 2/20 0.44
CYP17A1 P05093 1/20 0.44
WNT1 P04628 1/20 0.43
UHRF1 Q96T88 1/20 0.42
WNT3A P56704 1/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
CYP2E1 P05181 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18174642 0.81 DHODH (0.46) DYRK1ANFATC1ABL1CYP11B1CYP11B2
SCHEMBL18174787 0.81 DHODH (0.46) DYRK1ANFATC1ABL1CYP11B1CYP11B2
SCHEMBL18174718 0.80 CYP17A1 (0.44) DYRK1ANFATC1ABL1CYP11B1CYP11B2
SCHEMBL14900842 0.80 CYP11B1 (0.51) DYRK1ANFATC1ABL1CYP11B1CYP11B2
SCHEMBL21105125 0.80 RPS6KA3 (0.54) DYRK1ANFATC1UHRF1WNT3ACCNC
SCHEMBL18899879 0.78 ABL1 (0.74) ABL1CYP11B1CYP11B2
SCHEMBL30947586 0.78 ABL1 (0.47) ABL1CYP11B1CYP11B2CYP1A2CYP17A1
SCHEMBL15161092 0.78 CYP17A1 (0.47) DYRK1ANFATC1ABL1CYP11B1CYP11B2
SCHEMBL22426647 0.77 PDK2 (0.47) DYRK1ANFATC1CYP1A2UHRF1CCNC
SCHEMBL30906620 0.76 DYRK1A (0.51) DYRK1ANFATC1CYP11B1CYP11B2WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387982-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387982-A1 HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF LCK, SRC, CILK1 DYRK1A 131/4885NFATC1 384/4885ABL1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.